Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 59.32% | -304.14% | -147.29% | -73.13% | -69.38% |
| Total Depreciation and Amortization | -10.72% | -37.42% | -55.79% | -15.92% | -48.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.38% | 27.69% | 40.63% | 29.44% | 35.66% |
| Change in Net Operating Assets | 101.42% | -118.56% | 219.25% | -165.78% | -253.90% |
| Cash from Operations | 231.79% | -134.62% | -68.68% | -71.57% | -82.92% |
| Capital Expenditure | 74.83% | 24.00% | -17.34% | -65.04% | -252.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.16% | 134.45% | 83.99% | 70.05% | -62.98% |
| Cash from Investing | 130.63% | 133.99% | 83.53% | 69.64% | -63.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 34.54% | 13.80% | -11.76% | 6.92% | -33.07% |
| Repurchase of Common Stock | 100.00% | 100.00% | 20.17% | 20.17% | 20.17% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 36.66% | 15.61% | -11.56% | 7.65% | -33.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 234.48% | 264.43% | 134.87% | 82.55% | -255.52% |